Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 362,152 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 10,000 · Balance 372,152 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Row 2 · 2026-08-10 · Sale · Disposed 10,000 · Balance 362,152 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2033-04-05 | Direct | 110,546 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 10,000 · Balance 110,546 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Relay Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-08 | Direct | 32,947 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 32,947 · Balance 32,947 F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2025 Filed Oct 20, 2025 20:11 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 24,103 | $3.79 | $91,345.55 |
DisclosureSEC source: 0002034671-25-000006 · wk-form4_1760991057.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 22:00 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,289 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034671-25-000003 · wk-form4_1760565614.xml · derivative · entry 6 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,373 Underlying: Common Stock · 13,289 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 22:00 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 13,289 | $18.84 | $250,391.34 |
DisclosureSEC source: 0002034671-25-000003 · wk-form4_1760565614.xml · nonDerivative · entry 4 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,892 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 22:00 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 13,289 | $3.79 | $50,362.65 |
DisclosureSEC source: 0002034671-25-000003 · wk-form4_1760565614.xml · nonDerivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 22:00 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,445 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034671-25-000003 · wk-form4_1760565614.xml · derivative · entry 5 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,662 Underlying: Common Stock · 11,445 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 22:00 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 11,445 | $18.92 | $216,545.12 |
DisclosureSEC source: 0002034671-25-000003 · wk-form4_1760565614.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,892 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.635, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 22:00 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 11,445 | $3.79 | $43,374.26 |
DisclosureSEC source: 0002034671-25-000003 · wk-form4_1760565614.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:16 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 421,241 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000950170-25-084838 · ownership.xml · derivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,241 Underlying: Common Stock · 421,241 shares Expires 2035-06-08 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments after June 9, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.